Cryoport says cryopreservation supports commercial-scale cell therapy manufacturing
CYRX•Cryoport says cryopreservation can support more predictable commercial-scale cell therapy manufacturing. It says qualified inventories of frozen starting materials can improve manufacturing flexibility, reduce disruption risks and support entry into new markets.
1. Manufacturing flexibility
Cryoport’s analysis says fresh-material workflows become harder to scale because collection-dependent scheduling constrains capacity utilization and geographic expansion. Qualified inventories of cryopreserved starting materials can improve manufacturing flexibility, reduce disruption risks and support entry into new markets.
